SEARCH:   Advanced

Blood, 1 May 2005, Vol. 105, No. 9, pp. 3420-3427. Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-08-2977. This Article Full Text (PDF) All Versions of this Article: 2004-08-2977v1 105/9/3420    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moore, J. O Articles by Schiffer, C. A Search for Related Content PubMed PubMed Citation Articles by Moore, J. O Articles by Schiffer, C. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 13, 2004 Accepted November 15, 2004 Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: cancer and leukemia group B study 9222 Joseph O Moore, Stephen L George, Richard K Dodge, Philip C Amrein, Bayard L Powell, Jonathan E Kolitz, Maria R Baer, Frederick R Davey, Clara D Bloomfield, Richard A Larson*, and Charles A Schiffer Duke University Medical Center, Durham, NC, USA Duke University Medical Center, Durham, NC, USA; CALGB Statistical Center, Durham, NC, USA Massachusetts General Hospital, Boston, MA, USA Wake Forest University School of Medicine, Winston-Salem, NC, USA North Shore University Hosptial, Manhasset, NY, USA Roswell Park Cancer Institute, Buffalo, NY, USA State University of New York Upstate Medical Center, Syracuse, NY, USA The Ohio State University, Columbus, OH, USA The University of Chicago, Chicago, IL, USA Wayne State University, Detroit, MI, USA * Corresponding author; email: rlarson{at}medicine.bsd.uchicago.edu. CALGB study 9222 tested the hypothesis that treatment intensification of acute myeloid leukemia (AML) in first remission with multiple chemotherapy agents is superior to high-dose cytarabine (HiDAC) alone. We enrolled 474 patients < 60 years old with untreated de novo AML. Daunorubicin and cytarabine resulted in complete remission (CR) in 342 patients (72%), and 309 of these patients were randomized to receive one of 2 different intensification regimens. The first regimen consisted of 3 courses of HiDAC. The second regimen consisted of one course of HiDAC, a second course with etoposide and cyclophosphamide, and a third course with diaziquone and mitoxantrone. After a median follow-up time of 8.3 years, the median survival for all randomized patients was 2.8 years (95% CI, 1.9 -6.8 years). There was no difference in DFS between the two regimens (p=0.66). The median disease-free survival (DFS) was 1.1 years (95% CI, 0.9 -1.7 years) for patients receiving HiDAC and 1.0 year (95% CI, 0.9 -1.3 years) for those receiving multiagent chemotherapy. Cytogenetics was the only pretreatment characteristic prognostic for DFS, but there was no evidence of a differential treatment effect within cytogenetic risk groups. Toxicity was greater with multiagent chemotherapy. These two postremission regimens produce similar outcomes. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. M. Hartford, S. Duan, S. M. Delaney, S. Mi, E. O. Kistner, J. K. Lamba, R. S. Huang, and M. E. Dolan Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity Blood, March 5, 2009; 113(10): 2145 - 2153. [Abstract] [Full Text] [PDF] E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, January 1, 2009; 94(1): 102 - 112. [Abstract] [Full Text] [PDF] P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al. Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study J. Clin. Oncol., August 20, 2006; 24(24): 3904 - 3911. [Abstract] [Full Text] [PDF] R. A. Larson, R. M. Stone, R. J. Mayer, and C. A. Schiffer Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin. Cancer Res., June 1, 2006; 12(11): 3556s - 3563s. [Abstract] [Full Text] [PDF] J. E. Kolitz, S. L. George, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. De Angelo, T. Shea, W. Stock, V. Hars, et al. A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 407 - 407. [Abstract] G. Marcucci, K. Mrozek, A. S. Ruppert, K. Maharry, J. E. Kolitz, J. O. Moore, R. J. Mayer, M. J. Pettenati, B. L. Powell, C. G. Edwards, et al. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study J. Clin. Oncol., August 20, 2005; 23(24): 5705 - 5717. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020